New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
08:25 EDTCDXC, CDXC, SNTI, SNTI, ETAK, ETAK, TWER, TWER, ANDA, ANDA, SFE, SFE, ABMD, ABMD, TALN, TALN, AXGN, AXGN, PED, PEDNoble Financial Capital Markets to host a conference
10th Annual Equity Conference is being held in Sandpiper Bay, Florida on January 19-22 with webcasted company presentations to begin on January 22 at 8:30 am; not all company presentations may be webcasted. Webcast Link
Check below for free stories on CDXC;AXGN;TALN;ABMD;SFE;ANDA;TWER;ETAK;SNTI;PED the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
17:06 EDTABMDTrial results from Abiomed RECOVER RIGHT show survival rate of 73%
Abiomed announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption study of the Impella RP System. The clinical trial results demonstrated a survival rate of 73% in the overall patient population. Overall, the survival rate was 73% in the entire population at 30 days. Cohort A showed a survival rate of 83.3% and Cohort B had a 58.3% survival rate at 30 days.
September 15, 2014
07:21 EDTABMDHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 9, 2014
08:15 EDTSNTISenesco Technologies to change name to Sevion Therapeutics
Senesco Technologies announced a corporate rebranding under which the company will change its name to Sevion Therapeutics, Inc. The company will continue to trade as SNTI until a new ticker symbol is obtained. The rebranding and new corporate identity are first steps in fulfilling the company’s goal of becoming a preeminent, next-generation biologics company with best- and first-in-class product candidates and technologies.
07:29 EDTTWERUBM Canon to hold a summit
Subscribe for More Information
September 8, 2014
08:40 EDTPEDPacific Energy Development announces completion of drilling of Loomis 2-1H well
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use